Regencell Bioscience Holdings RGC
NASDAQ RGC
$6.17 -0.03 (-0.48%)
As of: Sep 30, 2026 · 10:20 AM EDT

Regencell Bioscience Holdings (RGC) Operating Leases (2022 - 2025)

Updated

Regencell Bioscience Holdings' Operating Leases came in at $128,178 for the quarter ended Dec 31, 2025.

Analysis

Regencell Bioscience Holdings (RGC) Operating Leases (2022 - 2025) Analysis & Trends

As of Jun 30, 2025, Regencell Bioscience Holdings' Operating Leases was $231,635, up 793.2% from the prior year.

  • Operating Leases carries a three-year compound annual growth rate of -13.7% (years ended Jun 2022 to Jun 2025).
  • Going back by year, Operating Leases was $25,934 in the year ended Jun 30, 2024 (+2.1%), $25,406 in the year ended Jun 30, 2023 (-92.9%) and $360,268 in the year ended Jun 30, 2022.
  • The figure for the quarter ended Dec 31, 2025 represents the lowest quarterly Operating Leases since the quarter ended Jun 30, 2024.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 655.56 Bn 574.09 Bn 17.26 Bn
2 AbbVie 470.94 Bn 444.10 Bn 12.70 Bn
3 Merck 367.14 Bn 321.57 Bn 12.21 Bn
4 Novartis Ag 280.33 Bn 236.20 Bn 11.24 Bn
5 Astrazeneca 257.78 Bn 231.34 Bn 12.86 Bn
6 Amgen 226.04 Bn 181.44 Bn 7.24 Bn
7 Gilead Sciences 188.89 Bn 163.01 Bn 6.22 Bn
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn
9 Vertex Pharmaceuticals 133.68 Bn 105.69 Bn 2.84 Bn
10 Regencell Bioscience Holdings 80.68 Mn 73.90 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 128,178.00
Jun 30, 2025 231,635.00
Jun 30, 2024 25,934.00
Jun 30, 2023 25,406.00
Jun 30, 2022 360,268.00
API Access

Regencell Bioscience Holdings Operating Leases API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=operating-leases&ticker=RGC&period=max&api_key=YOUR_API_KEY